Acute febrile rash (exanthem): when are tests needed? Measles, Kawasaki disease, drug eruption, primary HIV infection
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Suspected measles: confirm and notify without delay
- Notify the ARS (regional health agency) without delay (telephone, email) as soon as clinically suspected, then complete the mandatory notification form, without waiting for the result.
Laboratory confirmation
- Measles virus RNA by RT-PCR on an oropharyngeal sample (preferably in the first days of the rash; state the date of rash onset, contact and vaccination status)
- Measles serology IgM and IgG (from day 3 of the rash; or salivary IgM with the kit supplied by the ARS)if neededSerum or salivary IgM testing is possible from day 3 after the start of the rash, with oropharyngeal RT-PCR remaining preferred [2]. An IgM result is meaningful only in the absence of vaccination in the previous 2 months [3]. The NABM provides for serology in addition to PCR in a patient already immune (previous measles or vaccine) [4].
Do not order
Suspected Kawasaki disease: refer the same day
- Fever for 5 days or more with suggestive signs (even if they have disappeared): refer to the paediatric emergency department the same day, without prior tests in the community.
- The tests (FBC, CRP, albumin, transaminases, urine tests, echocardiography) are done in hospital.
Do not order
Rash on medication: look for a severe cutaneous drug reaction
- Skin detachment, blisters, mucosal erosions (eyes, mouth, genitals), fever > 39 °C with impaired general condition: stop the suspected drug and refer to the emergency department, without tests in the community (epidermal necrolysis).
Suspected DRESS (fever, facial oedema, lymphadenopathy): stop the drug and arrange hospital admission the same day; if these tests are done in the community, they must not delay admission
- FBC with blood film examination (eosinophils, atypical lymphocytes)
- Full liver function tests: AST
- ALT
- GGT
- Alkaline phosphatase
- Bilirubin
- Serum electrolytes
- Urea
- Serum creatinine with eGFR
- PT (prothrombin time)
Urine tests
- Urine dipstick (proteinuria, haematuria)
- Urine protein:creatinine ratio (if dipstick positive for protein)if needednon-French guidelineDRESS involves visceral damage in 91% of cases [14]; proteinuria on dipstick must be quantified (see the page “Proteinuria”).
Do not order
Adolescent or adult: febrile exanthem with lymphadenopathy or ulcers (primary HIV infection?)
Laboratory tests
- HIV serology (combined screening test)
- HIV-1 viral load (plasma RNA): acute infectious syndrome compatible with primary infectionif neededThe NABM covers HIV-1 viral load in adults and adolescents with any acute infectious syndrome compatible with HIV primary infection; HIV-2 primary infections are exceptional in France [4].
- Syphilis serology (depending on exposure)if neededRisky sexual exposure: see the pages “Sexually transmitted infections” and “Syphilis: positive serology” for the full tests.
Typical viral exanthem in a child in good general condition
- No laboratory tests: assess severity (child's fever, purpura) and review if the rash changes or if the fever lasts 5 days or more.
Also consider
- Rash that does not blanch on glass pressure? A rash that does not blanch on glass pressure is a high-risk sign: see the page "Purpura, bruising, bleeding".
Sources (24)
- Santé publique France. Rougeole : bilan annuel de la surveillance, année 2025. Bulletin national, 18 mai 2026.
- Direction générale de la santé. DGS-Urgent n° 2025_08 du 7 mars 2025 : vigilance renforcée dans le cadre de la recrudescence de la rougeole en France (diffusé par l'ARS Grand Est).
- Santé publique France. Rougeole : notre action (critères de signalement et définition des cas). Page consultée le 11 octobre 2026.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 5270 (ARN du virus de la rougeole), 1768-1770 (sérologie rougeole) et 4122 (charge virale VIH).
- UK Health Security Agency. National measles guidelines, version 8, juillet 2026.
- Robert Koch-Institut. RKI-Ratgeber Masern, version du 14 novembre 2024.
- Gregory DS, Shah SS, England BL. Measles: Rapid Evidence Review. Am Fam Physician. 2026;114(4), publié en ligne le 15 octobre 2026.
- National Institute for Health and Care Excellence. Fever in under 5s: assessment and initial management. NICE guideline NG143, 7 novembre 2019, mise à jour du 26 novembre 2021 (recommandations 1.2.25 à 1.2.27, tableau 2).
- Marchesi A, Rigante D, Cimaz R, Ravelli A, Tarissi de Jacobis I, Rimini A, et al. Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. Ital J Pediatr. 2021;47(1):16.
- Centre de référence des maladies auto-inflammatoires et de l'amylose inflammatoire (CeRéMAIA), filière FAI2R, Haute Autorité de santé. Maladie de Kawasaki. Synthèse à destination du médecin traitant, extraite du PNDS, septembre 2022.
- McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135:e927-99.
- Darby JB, Jackson JM. Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison. Am Fam Physician. 2021;104(3):244-252.
- The Royal Children's Hospital Melbourne. Kawasaki disease. Clinical Practice Guideline (approuvé par le Paediatric Improvement Collaborative), mise à jour de janvier 2026.
- Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071-80.
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, Haute Autorité de santé. Nécrolyse épidermique de l'adulte (syndromes de Stevens-Johnson et de Lyell). Synthèse à destination du médecin traitant, extraite du PNDS, novembre 2023.
- Centre de référence des dermatoses bulleuses toxiques et toxidermies graves TOXIBUL, groupe Toxidermies de la Société française de dermatologie. Protocole national de diagnostic et de soins (PNDS) : DRESS de l'adulte et de l'enfant, 2024 (publié par la HAS en novembre 2024).
- National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Clinical guideline CG183, 3 septembre 2014.
- Usatine RP, Sandy N. Dermatologic Emergencies. Am Fam Physician. 2010;82(7):773-780.
- Cabañas R, Ramírez E, Sendagorta E, et al. Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-253.
- Palfreeman A, Sullivan A, Rayment M, et al. British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020. HIV Med 2020;21(Suppl 6):1-26.
- Goldschmidt R, Chu C. HIV Infection in Adults: Initial Management. Am Fam Physician. 2021;103(7):407-416.
- Filière MCGRE. Protocole national de diagnostic et de soins (PNDS) : syndromes drépanocytaires majeurs de l'enfant et de l'adolescent, mars 2024 (HAS, mai 2024).
- Servey JT, Reamy BV, Hodge J. Clinical Presentations of Parvovirus B19 Infection. Am Fam Physician. 2007;75(3):373-376.
- Saguil A, Kane SF, Lauters R, Mercado MG. Hand-Foot-and-Mouth Disease: Rapid Evidence Review. Am Fam Physician. 2019;100(7):408-414.